Soteria Biotherapeutics Inc., a company developing switchable bispecific T-cell engagers to treat patients with solid tumors, has raised $42 million in series A financing to fund early development of a pipeline of candidates with potential in validated cancer targets, it said. Roche Venture Fund and 5AM Ventures led the round, with further investments from M Ventures, Novartis Venture Fund and Alexandria Venture Investments.
HONG KONG – Splisense Ltd. has closed a $28.5 million series B financing that it said will support pipeline development including its lead antisense oligonucleotide candidate, SPL84-23, for the potential treatment of cystic fibrosis. The Jerusalem-based company, which develops mRNA-altering therapies for CF and other genetic pulmonary diseases, attracted support for the round from Orbimed, Israel Biotech Fund, Biotel Ltd. and the Cystic Fibrosis Foundation.
Shanghai-based Elpiscience Biopharmaceuticals Co. Ltd. raised $105 million in a series C financing round to move candidates, starting with an anti-CD39 antibody, into clinical studies in the U.S. The funds will also support the company’s efforts in finding new mechanisms for cancer immunotherapy and potential partners, it said.
Flare Therapeutics Inc. emerged from stealth mode with $82 million in series A financing and an ambitious agenda to systematically drug transcription factors associated with cancer and other neurological, genetic and immunological conditions.
Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.
Business development among biopharmaceutical companies working on therapeutics for cancer indications has been brisk this year, with 32% of the 654 deals recorded to date by BioWorld involving cancer indications. However public companies in the area haven’t gained much investor enthusiasm, with the BioWorld Cancer index dropping over 18% year-to-date, with 6% of the loss in valuation taking place this month.
Biopharma startups seeking a mix of financial, strategic and operational support gained a new option May 12 with the announcement of Perceptive Xontogeny Venture Fund II from Perceptive Advisors LLC. The fund, expected to lead series A financings in the range of $20 million to $40 million closed with $515 million in capital commitments. It's led by portfolio manager and CEO Chris Garabedian, who also serves as chairman and CEO of Xontogeny LLC, a Boston-based accelerator.
RSS
